2,4-thiazolidinedione has been researched along with Hypertension in 9 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both metformin and thiazolidinedione derivatives(TZDs) improve insulin resistance, a major pathogenesis of type 2 diabetes, and decrease blood glucose levels without stimulating insulin secretion." | 4.82 | [Insulin-sensitizing agents: metformin and thiazolidinedione derivatives]. ( Satoh, J, 2003) |
| "For now, the goals and methods of treating hypertension and dyslipidemia are the same in people with the metabolic syndrome as in the general population." | 2.41 | A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia. ( Hoogwerf, BJ; Nambi, V; Sprecher, DL, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ketsawatsomkron, P | 1 |
| Pelham, CJ | 1 |
| Groh, S | 1 |
| Keen, HL | 1 |
| Faraci, FM | 1 |
| Sigmund, CD | 1 |
| Mori, S | 1 |
| Tyagi, S | 1 |
| Sharma, S | 1 |
| Budhiraja, RD | 1 |
| Nambi, V | 1 |
| Hoogwerf, BJ | 1 |
| Sprecher, DL | 1 |
| Gurnell, M | 1 |
| Savage, DB | 1 |
| Chatterjee, VK | 1 |
| O'Rahilly, S | 1 |
| Satoh, J | 1 |
| Wolffenbuttel, BH | 1 |
| van Haeften, TW | 1 |
| Kasuga, M | 1 |
| Hunabiki, A | 1 |
| Morita, S | 1 |
| Medina, G | 1 |
| Sewter, C | 1 |
| Puig, AJ | 1 |
8 reviews available for 2,4-thiazolidinedione and Hypertension
| Article | Year |
|---|---|
Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature?
Topics: Animals; Blood Pressure; Endothelium, Vascular; Genes, Dominant; Humans; Hypertension; Insulin Resis | 2010 |
[Pharmacotherapy of osteoporosis accompanied by lifestyle-related diseases].
Topics: Adrenergic beta-Antagonists; Animals; Cardiovascular Diseases; Diabetes Complications; Diphosphonate | 2011 |
A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia.
Topics: Angiotensin-Converting Enzyme Inhibitors; Female; Humans; Hyperinsulinism; Hypertension; Hypertrigly | 2002 |
The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation.
Topics: Adipose Tissue; Animals; Arteriosclerosis; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agent | 2003 |
[Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
Topics: Adipocytes; Adiponectin; Cyclic AMP-Dependent Protein Kinases; Diabetes Complications; Diabetes Mell | 2003 |
Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
Topics: Acarbose; Aldehyde Reductase; Biguanides; Diabetes Mellitus, Type 2; Glucose; Guanidines; Humans; Hy | 1995 |
[Etiology and therapy of insulin resistance].
Topics: Animals; Arteriosclerosis; Biguanides; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertens | 1999 |
[PPARgamma and thiazolidinediones, something more than a treatment for diabetes].
Topics: Arteriosclerosis; Cell Differentiation; Cell Transformation, Neoplastic; Diabetes Mellitus, Type 2; | 2000 |
1 other study available for 2,4-thiazolidinedione and Hypertension
| Article | Year |
|---|---|
Effect of phosphatidylinositol 3-kinase-γ inhibitor CAY10505 in hypertension, and its associated vascular endothelium dysfunction in rats.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Atorvastatin; Blood Pressure; Desoxycorticosterone; Endothe | 2012 |